Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | -69.13% | -76.40% | 84.16% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -69.13% | -76.40% | 84.16% | -- | -- |
| Cost of Revenue | -136.40% | -138.81% | 85.64% | -- | -- |
| Gross Profit | -40.84% | -51.20% | 83.88% | -- | -- |
| SG&A Expenses | 80.40% | 24.87% | -1.39% | -- | -- |
| Depreciation & Amortization | 63.40% | 50.00% | 31.63% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.42% | 2.76% | 28.97% | -- | -- |
| Operating Income | -400.43% | -541.36% | 15.00% | -- | -- |
| Income Before Tax | -207.82% | -191.27% | -4.94% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -207.82% | -191.27% | -4.94% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -207.82% | -191.27% | -4.94% | -- | -- |
| EBIT | -400.43% | -541.36% | 15.00% | -- | -- |
| EBITDA | -464.59% | -704.26% | 15.41% | -- | -- |
| EPS Basic | -177.36% | -175.00% | 1.45% | -- | -- |
| Normalized Basic EPS | -172.73% | -168.00% | 2.33% | -- | -- |
| EPS Diluted | -177.36% | -175.00% | 1.45% | -- | -- |
| Normalized Diluted EPS | -172.73% | -168.00% | 2.33% | -- | -- |
| Average Basic Shares Outstanding | 7.45% | 4.33% | 4.79% | -- | -- |
| Average Diluted Shares Outstanding | 6.85% | 3.74% | 5.36% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |